A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia

INTRODUCTION: Tumor hypoxia causes resistance to radiation and chemotherapy. Evofosfamide (TH-302) has exhibited specific hypoxia-dependent cytotoxicity against primary acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) samples in vitro. Based on these findings, a Phase I study of e...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am J Hematol
Main Authors: Badar, Talha, Handisides, Damian R., Benito, Juliana M., Richie, Mary Ann, Borthakur, Gautam, Jabbour, Elias, Harutyunyan, Karine, Konoplev, Sergej, Faderl, Stefan, Kroll, Stew, Andreeff, Michael, Pearce, Tillman, Kantarjian, Hagop M., Cortes, Jorge E., Thomas, Deborah A., Konopleva, Marina
Format: Artigo
Sprog:Inglês
Udgivet: 2016
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4946992/
https://ncbi.nlm.nih.gov/pubmed/27169385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24415
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker